In turn, this novel network between POSTN and osteogenic induction during degenerative bone disease may provide novel targets and strategies for the development of alternative therapies and biomarkers for postmenopausal osteoporosis. This evidence concerns the gene POSTN and postmenopausal osteoporosis.